Astra works to avoid a datopotamab double dip
As Tropion-Breast01 is toplined positive Astra ensures the markets know that overall survival isn’t a washout.
Novartis goes 0 for 2 in PD-1 blockade
BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.
